Medical device start-ups have closed on some impressive venture capital funding rounds so far this year, with the largest investments concentrated in a few “hot” technology areas, including companies with office-based sinus treatments, technologies aimed at obesity, neuromodulation devices, atrial fibrillation technologies, and transcatheter heart valve devices. However, according to the latest report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA), the biotechnology industry garnered far more VC funding in Q2 than did the medical device sector, particularly with regards to early-stage funding.
Notable device rounds completed in the first half of the year included a $30 million Series D closed in March by Intersect ENT Inc.[See Deal], a developer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?